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and DevePurpose: To compare pretreatment scans with perfusion computed tomography (pCT) vs. dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI) in rectal tumors.
Methods and Materials: Nineteen patients diagnosed with rectal cancer were included in this prospective study. All
patients underwent both pCT and DCE-MRI. Imaging was performed on a dedicated 40-slice CT–positron
emission tomography system and a 3-T MRI system. Dynamic contrast enhancement was measured in tumor tissue
and the external iliac artery. Tumor perfusion was quantified in terms of pharmacokinetic parameters: transfer
constant Ktrans, fractional extravascular–extracellular space ve, and fractional plasma volume vp. Pharmacokinetic
parameter values and their heterogeneity (by 80% quantile value) were compared between pCT and DCE-MRI.
Results: Tumor Ktrans values correlated significantly for the voxel-by-voxel–derived median (Kendall’s
t correlation, t = 0.81, p < 0.001) and 80% quantile (t = 0.54, p = 0.04), as well as for the averaged uptake
(t = 0.58, p = 0.03). However, no significant correlations were found for ve and vp derived from the voxel-by-
voxel–derived median and 80% quantile and derived from the averaged uptake curves.
Conclusions: This study demonstrated for the first time that pCT provides Ktrans values comparable to those of
DCE-MRI. However, no correlation was found for the ve and vp parameters between CT and MRI. Computed
tomography can serve as an alternative modality to MRI for the in vivo evaluation of tumor angiogenesis in terms
of the transfer constant Ktrans.  2010 Elsevier Inc.
Perfusion CT, DCE-MRI, Pharmacokinetic model, Rectal cancer, Tumor perfusion.INTRODUCTION
Perfusion computed tomography (pCT) and dynamic con-
trast-enhanced magnetic resonance imaging (DCE-MRI)
are clinical imaging techniques that are increasingly applied
to noninvasively assess the microvascular status of tumor tis-
sue (1–3). In clinical cancer research, regression of tumor
microvasculature is considered an important early surrogate
marker for treatment response, before reductions in tumor
volume become apparent. To date, both pCT and DCE-
MRI are increasingly used for the prediction and evaluation
of treatment response (4–6), as indicators of tumor angiogen-
esis (7–9), and for primary tumor staging (10). Computed
tomography has the advantage of generally being more easily
accessible compared with MRI. Moreover, the majority oft requests to: Hugo J. W. L. Aerts, M.Sc., Department of
Oncology (MAASTRO), Maastricht University,
laan 12, 6202 AZ Maastricht, The Netherlands. Tel:
88-44-55-666; Fax: (+31) (0) 88-44-55-667; E-mail:
ts@maastro.nl
ted by the Netherlands Organization for Health Research
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400patients with solid tumors receive radiotherapy for which
CT or CT–positron emission tomography (PET) examina-
tions are applied. Therefore, the use of pCT in the assessment
of tumor microcirculation could lead to important logistical
advantages.
Both pCT and DCE-MRI are imaging modalities that rely
on the dynamic assessment of tracer uptake kinetics, subse-
quently quantified by means of pharmacokinetic models
(11). These models describe, in terms of pharmacokinetic pa-
rameters, the wash-in and wash-out of contrast agent from the
microvasculature into the surrounding tissues. A commonly
applied pharmacokinetic two-compartment model is the ex-
tended Kety model, which consists of the (transendothelial)
volume transfer constant Ktrans (in min1), the fractionaland financial support provided by Siemens.
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the fractional blood plasma volume vp. Clinically, K
trans is the
most valuable pharmacokinetic parameter, which describes
the transfer rate of the contrast agent from the plasma space
to the EES, and represents a combination of microvascular
blood flow, vessel wall permeability, and vessel density
(i.e., permeability surface area product) (11).
Although the principles of pCT and DCE-MRI are similar,
the physical principles, imaging protocols, pharmacokinetic
properties of contrast agents, and injection protocols strongly
differ. Because contrast enhancement not only depends on
the microvasculature of the tissue under study but also on
the imaging method, a priori it is unknown to what extent dif-
ferent imaging modalities provide comparable quantitative
information on the tumor microcirculation, in terms of reli-
able pharmacokinetic parameter estimates.
The objective of this study was to compare the pharmaco-
kinetic parameters characterizing tumor microcirculation,
derived from pretreatment pCT and DCE-MRI scans in rectal
cancer patients.METHODS AND MATERIALS
Patient characteristics
From November 2007 to September 2008, a total of 19 patients
(15 men and 4 women, aged 64.3  7.2 years) were included. All
patients were diagnosed with non–locally advanced primary
resectable rectal cancer, Stage I–III according to International
Union Against Cancer criteria. After the pCT and DCE-MRI ex-
amination, all patients were treated with 5 fractions of 5 Gy radio-
therapy on 5 consecutive days, which was followed by total
mesorectal excision within 3 days of the last radiotherapy fraction.
The local medical ethics committee approved the trial, according
to Dutch law. Patients gave written informed consent before inclu-
sion.CT-PET and pCT
The CT-PET and pCT examinations were performed on a dedi-
cated Siemens TruePoint Biograph 40 PET-CT simulator (Siemens
Medical, Erlangen, Germany). A static CT-PET scan was performed
for tumor detection, delineation, and radiotherapy treatment plan-
ning. For the PET scan, an intravenous injection of (weight [kg]
 4 + 20) MBq fluorodeoxyglucose (FDG) (GE Healthcare, Eind-
hoven, The Netherlands) was performed, followed by 10 mL saline.
After a 60-min uptake period, CT-PET images were acquired. The
static CT scan was performed without iodine contrast. For the
PET scan, three bed positions, each of 5 min, were acquired. Com-
puted tomography–based attenuation, three-dimensional scatter cor-
rection, and decay correction were performed during reconstruction
of the PET scan.
In addition to the routine CT-PET protocol, a pCT was
performed. The scanning range for the perfusion scan was defined
by an expert radiation oncologist (J.B. or G.L). The pCT scan was
performed using an iodinated contrast agent with a concentration
of 300 mg iodine/mL (Xenetix 300; Guerbet, Aulnay-sous-Bois,
France). A volume of 60 mL (n = 13) and 120 mL (n = 6) of contrast
agent was injected at a rate of 3 mL/s with an automatic injector
(Stellant CT Injection System; MedRad, Warrendale, PA) into the
antecubital fossa. It was found that the vascular input functions
were abnormally shaped (possibly reflecting multiple recirculations)on our CT system for 120-mL injections. Therefore, we adapted the
protocol during the study to 60 mL, which yielded better results. The
pCT scan was performed in static cine mode and contained
12 contiguous slices with a reconstructed slice thickness of
2.4 mm, a field of view (FOV) of 500 mm, and an image size of
512  512. Other acquisition settings were as follows: tube voltage
80 kVp, tube current 140 mAs, rotation time 1 s, and total acquisi-
tion time 100 s.
DCE-MRI
Dynamic contrast-enhanced MRI was performed on a clinical 3-T
MRI system (Achieva; Philips Medical Systems, Best, The Nether-
lands) equipped with a five-element cardiac phased-array coil. Sag-
ittal and transverse T2-weighted anatomic images of the abdominal
and tumor region were acquired according to the location of the pre-
viously acquired CT images. To obtain MR slices in the same orien-
tation as the CT images, all MR slices were angulated perpendicular
to the table. To determine the precontrast T1 relaxation time of the
tumor and gluteus muscle, nine T1-weighted scans (three-dimen-
sional fast gradient recalled gradient echo) were acquired with dif-
ferent flip angles (1, 2, 3, 5, 7, 10, 15, 25, and 35),
repetition time 11 ms, echo time 4.6 ms, 10 transverse slices, slice
thickness 8 mm, matrix dimension 128  128, and pixel size
2  2 mm. The T1-weighted dynamic contrast-enhancement series
used the same sequence with a flip angle of 35 and comprised
125 volume acquisitions (acquisition time, 490 s) at a scan interval
of 3.92 s. At the start of the acquisition of the 11th dynamic volume,
the injection of the contrast agent was initiated. Gadopentetate dime-
glumine (0.2 mmol/kg body weight, 0.5 mmol/mL; Magnevist;
Schering, Berlin, Germany) was injected in the antecubital fossa
at a rate of 1 mL/s and flushed with 25 mL saline. This relatively
low injection rate consistently provided bolus-shaped vascular input
functions at 3 T. Higher injection rates gave rise to strong degrada-
tions of the bolus peak due to the T2* and susceptibility effects,
which was found in initial test acquisitions during the setup of the
DCE-MRI protocol (data not shown). For comparison, pCT and
DCE-MRI protocols are summarized in Table 1.
Pharmacokinetic analysis
Image coregistration. Automatic image registration between the
precontrast CT, pCT, and PET images was performed using an algo-
rithm based on mutual information (Focal software, version 4.34;
CMS, St. Louis, MO) (12). For every patient, the tumor was delin-
eated according to automatic standardized uptake value thresholding
of the PET data using the TrueD system (VC50; Siemens Medical,
Erlangen, Germany) (13, 14). The tumor delineations were projected
on the registered pCT. To ensure correct matching, the tumors on the
T2-weighted MR images were delineated by a radiation oncologist
specializing in rectal cancer (J.B.), with the knowledge of all MR,
CT, and PET image information. All voxels within tumor delinea-
tions on pCT and DCE-MRI were used for further pharmacokinetic
parameter analysis. All voxels within tumor delineations on pCT
and DCE-MRI were used for further pharmacokinetic parameter
analysis.
Data analysis. The acquired pCT data were downsampled from
0.98  0.98  2.4-mm to 3.92  3.92  4.8-mm voxels to
improve the signal-to-noise ratio (SNR). For both pCT and
DCE-MRI the relative signal change was derived by dividing
the measured signal-enhancement curves by the signal intensity
acquired from the precontrast baseline images. For pCT, the inten-
sity values were rescaled such that the intensity in air was zero, to
ensure that the CT value was proportional to the attenuation
Table 1. Overview of the application of pCT and DCE-MRI acquisition parameters and contrast agents
Parameter pCT DCE-MRI
Acquisition time (s) 100 490
Interscan interval (s) 1.00 3.92
Reconstructed pixel size (mm) 3.92  3.92* 2  2
Slice thickness (mm) 4.80* 8
Field-of-view (LR/AP/FH) (mm) 500  500  28.8 256  256  80
Contrast agent (CA) Iobitridol (300 mg/mL) Gadopentetate dimeglumine (0.5 mmol/mL)
CA molecular weight (g/mol) 835 938
CA viscosity (mPa$s) at 37C 6.0 2.0
Injection volume (mL) 60 or 120 30
Injection rate (mL/s) 3 1
Abbreviations: pCT = perfusion computed tomography; DCE-MRI = dynamic contrast-enhanced magnetic resonance imgaging; LR = left–
right, AP = anterior–posterior; FH = feet–head.
* Downsampled for pharmacokinetic analysis from reconstructed CT data.
402 I. J. Radiation Oncology d Biology d Physics Volume 77, Number 2, 2010coefficient and the contrast agent concentration. To correct for the
nonlinear relationship for MRI, the T1-weighted signal amplifica-
tion was fitted to the Ernst equation (15). The T1 relaxation time
before contrast agent injection (T10) was set to 1664 ms for arterial
blood at 3 T (16).
Pharmacokinetic model. For the quantification of the pCT and
DCE-MRI time series data, the extended Kety two-compartment
model was used (11), describing the tissue uptake of a contrast agent
from the blood plasma into the tissue by:







The blood plasma concentration curve (Cp) was derived from the
acquired whole-blood tracer concentration (Cb) divided by (1-Hct)
(17), with Hct = 0.45 the hematocrit value (11). For both DCE-
MRI and pCT the blood concentration was extracted from the right
external iliac artery. To improve the SNR, Cp was calculated byFig. 1. Contrast agent uptake curves in arterial and tumor tissue
puted tomography (A) and dynamic contrast-enhanced magnetic
curves (gray) and a tumor average uptake curve (black) of the tum
The signal-to-noise ratio of the DCE-MRI was superior in the tu
uptake curve.averaging the concentration time curves over all voxels selected
inside the iliac artery. The tumor tissue concentration curves (Ct)
were acquired from the time series data and extracted on a voxel-
by-voxel basis and on a tumor uptake curve–based average from
all tumor voxels. Pharmacokinetic data analysis was performed
using in-house-developed software in MATLAB (Mathworks,
Natick, MA). The concentration time curves from pCT and DCE-
MRI data were fitted to the pharmacokinetic model. Subsequently,
pharmacokinetic parameters were calculated using the Levenberg-
Marquardt algorithm (using the ‘‘lsqcurvefit’’ routine). The param-
eter boundaries were set to 0 # Ktrans # 5 min1, 0 # ve # 1, and
0 # vp #1 (18–20).Statistical analysis
All results were expressed as mean  standard deviation
(SD). The distributions of the voxel-by-voxel–derived pharma-
cokinetic parameter values were compared by histogramof a representative patient, resulting from perfusion com-
resonance imaging (DCE-MRI) (B). The voxel-by-voxel
or tissue are shown. Note the differences of the time axes.
mor tissue, for both the voxel-by-voxel and tumor average
Fig. 2. Comparison between computed tomography (A) and a T2-weighted magnetic resonance imaging (B) of a represen-
tative rectum cancer patient. The upper row displays the anatomic precontrast images, the lower row the Ktrans maps of the
muscle and tumor tissue regions, as indicated by the boxes in the anatomic images. Note that hyperintensities (i.e., Ktrans
$1 min1) in the Ktrans maps can only be observed in the tumor and not the gluteus muscle region.
Perfusion CT and MRI in rectal cancer. d R. G. J. KIERKELS et al. 403analysis and characterized by the corresponding median and the
80% quantile value of the histograms. Statistical correlations
between estimates were evaluated using the Kendall’s t correla-
tion coefficient and Bland-Altman plots. Differences were con-
sidered to be statistically significant when p < 0.05. The
differences between volume of interest (VOI)-based and
voxel-based (i.e., median and 80% quantile) values were tested
using the Wilcoxon signed-rank test.Fig. 3. Histograms of the pharmacokinetic-parameters Ktrans (A
voxel-by-voxel analysis of perfusion computed tomography (p
imaging (DCE-MRI) scans. The data are shown relative to the
deviation between patients. Note the similarities of the Ktrans
DCE-MRI–derived Ktrans values at increasing Ktrans (>0.6 minRESULTS
Patient characteristics
To compare pharmacokinetic parameters, individual pCT
and DCE-MRI scans were analyzed for every patient. In 15
of 19 patients, images suitable for comparative pharmacoki-
netic analysis were obtained. Four patients were excluded
owing to contrast agent leakage during injection or strong), ve (B), and vp (C) of the tumor tissue derived from the
CT) and dynamic contrast-enhanced magnetic resonance
analyzed tumor volume. Error bars denote the standard
distribution for both imaging modalities and the higher
1).
Fig. 4. Scatter plots (A) and Bland-Altman plots (B) of the median (dots) and the 80% quantile (circles) of the tumor phar-
macokinetic parameter Ktrans (Panel I), ve (Panel II), and vp (Panel III) of pCT versus DCE-MRI. Parameters were obtained
on the basis of a voxel-by-voxel pharmacokinetic analysis. The dotted line (A) represents perfect agreement between per-
fusion computed tomography (pCT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)–derived
parameters. The solid lines and dashed lines (B) indicate the mean difference and the 95% (1.96 SD) quantile limits of
the parameters derived from the two imaging modalities. The corresponding correlation coefficients and statistics are listed
in Table 2.
404 I. J. Radiation Oncology d Biology d Physics Volume 77, Number 2, 2010abdominal motion during pCT acquisition. All patients
underwent the DCE-MRI examination after the pCT exami-
nation (1.61  1.13 days). The total tumor volume (based
on the static CT-PET data) was 15.6  15.2 cm3.
Contrast enhancement
Figure 1 illustrates the contrast uptake curves for pCT and
DCE-MRI of a representative patient. Because of the longer
acquisition time, with MRI it is possible to measure the late
tracer kinetics in the artery and tumor tissue. The SNR of
the voxel-by-voxel tumor tissue curves was significantly
higher for DCE-MRI (20.1  6.4) compared with pCT
(6.7  5.3) (p < 0.01). In addition, the SNR of the mean tu-
mor uptake curves was significantly higher for DCE-MRI
(62.4  19.9) than for pCT (23.6  25.0) (p < 0.01).
Comparison images between pCT and DCE-MRI
An example of a voxel-by-voxel parameter map of Ktrans
for pCT and DCE-MRI is depicted in Fig. 2. Apparently there
is a visual agreement between the parameter maps. However,
some differences possibly introduced by differences inpatient position and bladder and rectum filling were
observed. For both imaging modalities it is evident that the
spatial distribution of Ktrans in healthy muscle tissue is rela-
tively homogeneous and values are low compared with tumor
tissue, in which Ktrans is more heterogeneously distributed
with local high-Ktrans regions.
Voxel-by-voxel parameters
The histograms of the voxel-by-voxel–determined phar-
macokinetic parameter estimates are shown in Fig. 3.
Similarities between the distributions of the pCT- and the
DCE-MRI–derived Ktrans values were observed (Fig. 3A).
However, DCE-MRI includes more high Ktrans values
(>0.6 min1). Overall, for ve higher values for DCE-MRI
were observed compared with pCT (Fig. 3B). The same
was observed for the distribution of vp (Fig. 3C).
The relationships between the voxel-by-voxel–derived
median and 80% quantile pharmacokinetic parameter values
derived from DCE-MRI and pCT are shown in Fig. 4. Both
the median Ktrans (t = 0.81, p < 0.001) and the 80% quantile
Ktrans (t = 0.54, p = 0.04) were significantly correlated




Tumor (mean  SD) Median  SD 80% quantile  SD
(Voxel analysis)
Muscle (median  SD)
Ktrans (min1)
pCT 0.30  0.16 0.34  0.13 0.57  0.18 0.08  0.05
DCE-MRI 0.53  0.37 0.37  0.14 0.69  0.23 0.13  0.08
Difference 0.23  0.26 (p = 0.002) 0.03  0.09 (p = 0.4) 0.16  0.08 (p = 0.1) 0.05  0.07 (p = 0.003)
Kendall’s t 0.58 (p = 0.03) 0.81 (p < 0.001) 0.54 (p = 0.04) 0.47 (p = 0.08)
ve
pCT 0.31  0.25 0.29  0.12 0.51  0.13 0.26  0.13
DCE-MRI 0.66  0.25 0.49  0.14 0.69  0.12 0.24  0.10
Difference 0.35  0.44 (p = 0.01) 0.20  0.21 (p = 0.005) 0.22  0.21 (p = 0.007) 0.03  0.18 (p = 0.4)
Kendall’s t 0.35 (p = 0.2) 0.19 (p = 0.5) 0.17 (p > 0.5) 0.24 (p = 0.4)
vp
pCT 0.04  0.04 0.02  0.02 0.06  0.05 7.310-3  4.010-3
DCE-MRI 0.08  0.06 0.12  0.09 0.30  0.14 5.310-3  9.510-3
Difference 0.04  0.05 (p = 0.005) 0.11  0.09 (p = 0.001) 0.24  0.13 (p < 0.001) 2.0103  9.7103
(p = 0.09)
Kendall’s t 0.23 (p = 0.4) 0.20 (p = 0.5) 0.02 (p = 0.5) 0.15 (p = 0.5)
Abbreviations: VOI = volume of interest; Ktrans = (transendothelial) volume transfer constant; ve = volume of extravascular–extracellular
space per unit volume of tissue; vp = blood plasma volume per unit volume of tissue; t = Kendall’s correlation coefficient. Other abbreviations
as in Table 1.
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derived median (p = 0.5) and 80% quantile (p = 0.5)
(Fig. 4AII). Additionally, the vp-derived median (p = 0.5)
and 80% quantile (p = 0.9) were not significantly correlated
(Fig. 4AIII). Table 2 lists all averaged pharmacokinetic pa-
rameters and statistical results.
The Bland-Altman plots in Fig. 4B demonstrate no signif-
icant differences between the medians and 80% quantile
values of Ktrans (p = 0.4 and p = 0.09, respectively)
(Fig. 4BI). The pCT-derived median and 80% quantile ve
values were both significantly lower than those of DCE-
MRI (p = 0.005 and p = 0.007, respectively) (Fig. 4BII).
Additionally, the derived median and 80% quantile vp values
were both significantly lower for pCT (p = 0.001 and
p < 0.001, respectively) (Fig. 4BIII).
For gluteus muscle tissue, the pCT-derived Ktrans was sig-
nificantly lower (0.08  0.05 min1) than that of DCE-MRI
(0.13 0.08 min1, p = 0.003) (Table 2). Values for ve and vp
in muscle, however, were not significantly different between
the two modalities (p = 0.4 and p = 0.1, respectively).Average tumor curve parameters
The pharmacokinetic parameters of the average tumor con-
trast uptake curves are shown in Fig. 5. Ktrans values corre-
lated significantly between pCT and DCE-MRI (t = 0.58,
p = 0.03). However, the ve and vp parameters did not signif-
icantly correlate (p = 0.2 and p = 0.4, respectively). Note that
for higher mean Ktrans the DCE-MRI–derived Ktrans
increased more than for pCT (Fig. 5).
The Bland-Altman plots in Fig. 5B demonstrated signifi-
cant differences between all pCT and DCE-MRI–derived
parameters. Table 2 lists the averaged parameter estimates
and statistical results. The Ktrans values were significantlylower for pCT (p = 0.002) (Fig. 5BI). Additionally, the
ve and vp were significantly lower for pCT (p = 0.01 and
p < 0.01, respectively) (Fig. 5BII and 5BIII).DISCUSSION
To our knowledge, this is the first study performing (1)
pCT and DCE-MRI in the same patients diagnosed with pri-
mary rectal cancer, and (2) DCE-MRI with pharmacokinetic
modeling at 3 T. Our study demonstrates that the transendo-
thelial transfer constant Ktrans derived from pCT is signifi-
cantly comparable to the one derived from DCE-MRI.
Therefore, CT can serve as an alternative modality to MRI
for the in vivo evaluation of tumor angiogenesis.
This study demonstrates that pCT allows for the noninva-
sive characterization of tumor perfusion, which can be
easily performed at the moment when CT is used for radio-
therapy treatment planning. Thus, pCT represents an attrac-
tive alternative to DCE-MRI in rectal cancer patients who
are referred for radiotherapy. However, the pCT scan will
expose the patient to additional ionizing radiation, whereas
DCE-MRI does not involve any ionizing radiation expo-
sure. In this regard, one has to compare this additional
radiation to the effective dose of an FDG-PET scan
(approximately 7 mSv), and particularly the fact that these
patients will receive a much higher dose due to the sched-
uled radiotherapy. In addition, the additional dose of pCT
has to be weighted against the relatively old age (frequently
>60 years) and life expectancies of these patients. However,
for relatively young patients and/or when MRI system
availability is no limitation, DCE-MRI is recommended
over pCT because of the better signal-to-noise characteris-
tics, stronger contrast uptake, more complete evaluation of
Fig. 5. Scatter plots (A) and Bland-Altman plots (B) of pharmacokinetic parameters Ktrans (Panel I), ve (Panel II), and vp
(Panel III), derived from the mean tumor uptake curve of the perfusion computed tomography (pCT) and dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI) scans. Each dot represents the data of one patient. The dotted line (A)
represents perfect agreement between pCT- and DCE-MRI–derived parameters. The black line indicates the results from
the Kendall’s t correlation test for Ktrans. In the Bland-Altman plot the solid line represents the mean of the difference be-
tween MRI and pCT, and the dashed lines indicate the 95% (1.96 SD) confidence intervals. Corresponding statistics are
listed in Table 2.
406 I. J. Radiation Oncology d Biology d Physics Volume 77, Number 2, 2010the microcirculatory environment of the tumor, larger tumor
coverage, and the absence of ionizing radiation. Qualifica-
tions of CT and MRI to perform perfusion imaging are sum-
marized in Table 3.
The acquisition time of pCT (100 s) was long enough to as-
sess measurements of tumor Ktrans, which correlated to those
of DCE-MRI (490 s) (21). In addition, the sampling time of
pCT (1 s) and DCE-MRI (3.92 s) was expected to be sufficient
for reliable estimation of Ktrans (22). Clinically, Ktrans is gen-
erally considered the most relevant perfusion parameter.
However, the discrepancy for the ve and vp parameters might
be explained by the fact that other factors (besides acquisition
time and sample frequency) influence the measurements of
the pharmacokinetic parameters—for example, differences
in contrast agent, day-to-day physiologic variations (e.g., car-
diac output), and signal-to-noise signal intensity characteris-
tics. However, for Ktrans the used sampling and acquisition
times of both pCT and DCE-MRI were sufficient. This was
demonstrated by the fact that the voxel-by-voxel–based me-
dian and 80% quantile value and the volume-averaged time
course–derived Ktrans were significantly correlated.To date, only two studies have reported on a comparative
study between pCT and DCE-MRI, unfortunately without
pharmacokinetic modeling. One study assessed the value of
pCT and DCE-MRI on solitary pulmonary nodules in terms
of peak enhancement values (23). More recently, Bisdas
et al. (24) concluded that the two imaging modalities were
equally suited to differentiate squamous cell carcinoma using
deconvolution-based analysis.
In the present study, differences were noticed between the
pharmacokinetic parameters derived from the voxel-by-voxel
analysis and the volume-averaged time course–derived param-
eters. The voxel-based Ktrans of pCT compared largely to those
of DCE-MRI. However, the estimation by the tumor volume
average–based analysis yielded higher values for DCE-MRI.
One explanation could be, from a micromorphologic and phys-
iologic point of view, that tumor tissue is strongly heteroge-
neous by nature. Moreover, the ability to detect both
hypervascular regions (related to angiogenesis) and hypovas-
cular regions (potentially related to hypoxia) is very important.
This means that adequate assessment of the tumor tissue
requires spatially resolved methods that reflect the
Table 3. CT and MRI characteristics for perfusion imaging
Parameter CT MRI
FH coverage Small (<3 cm) Large ($8 cm)
Image orientation Transverse Free, can be angulated perpendicular to rectum
Time resolution #1 s, allowing high temporal acquisition of
first pass of tracer
>3 s
Duration perfusion scan <2 min to limit radiation dose and tube heating Typically <12 min, allowing accurate contrast
agent washout acquisition
Soft-tissue contrast Low High on the basis of different relaxation times
Contrast agent Iodinated monomers Gadolinium chelates
Signal–concentration relationship Linear Only linear for low concentrations (<5 mM)
Safety Ionizing radiation, effective dose 15 mSv None*
SNR of dynamic uptake curves Typically <10 (depends on contrast agent
dose and rate)
<50 (depends on contrast agent dose)
Total examination duration 5 min 45 min
Availability High, frequently also in radiotherapy
departments
Low
Abbreviations: SNR = signal-to-noise ratio. Other abbreviations as in Table 1.
* When using particular MR contrast agents there is a very small chance of inducing nephrogenic systemic fibrosis in patients with severe
renal impairment.
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Therefore, physiologic properties derived from tumor-aver-
aged uptake measurement seem suboptimal. Another
important issue is the higher viscosity of the CT contrast agent
compared with the MRI agent (6.0 vs. 2.0 mPa$s). Because of
the relatively low viscosity of the MRI agent, it can more easily
enter tumor tissue regions, both in the capillary system as in the
interstitial space. To determine Ktrans, ve, and vp values, there
has to be some (minimal) amount of contrast agent in all tissue
compartments, which might not be the case for iodine. There-
fore, it is likely that the ve and vp parameter estimates are also
influenced by the viscosity of the contrast agent.
Our study is hampered by a few limitations. In general, per-
fusion measurements are intrinsically variable owing to inter-
nal and external factors, including day-to-day physiologic
variations (e.g. cardiac output); technical variability; observer
variability; tumor heterogeneity (25). Intermodality varia-
tions yielding, for example, differences in anatomic coverage;
and the relationship between measured signal intensity and
concentration of contrast agents. The limited craniocaudal
coverage of only 2.88 cm for pCT resulted for some patients
in an insufficient coverage of the rectal tumor in the imaging
volume. For such cases, pCT measurements were only ob-
tained from the region of maximum tumor coverage. Hence,
the FOV of DCE-MRI to be analyzed was manually adjusted
comparable to the FOV for pCT. The DCE-MRI and pCT
measurements could not be performed on the same day, owing
to the pharmacokinetic interference of the contrast agents
(iodine and gadolinium). However, the interval between
both acquisitions was preferred to be within 2 days. A valida-
tion with pathology was not feasible owing to the radiother-apy performed between the imaging and the total tumor
resection. However, several studies have already compared
the pCT- and DCE-MRI–derived angiogenic parameters
with histopathologic microcirculation parameters (26–28).
Because of differences in patient position and bladder and rec-
tum content, a comparison of the same voxel in the pCT and
DCE-MRI scans was very difficult. Accurate image registra-
tion between pCT and DCE-MRI is required but complicated
because of these differences. Available nonrigid registration
algorithms have a general lack of validation in rectal cancer
patients. Therefore, tumor delineation on CT and MRI was
performed separately, subsequently assessing the distribu-
tions of the pharmacokinetic parameter estimates. In the pres-
ent study, the delineation of the tumor volume was done by
one expert radiation oncologist by using MR and CT images
jointly. One might argue that this may introduce some bias
with respect to assessments if no MR images were available
or studies in which readers are blinded. However, we analyzed
whole three-dimensional tumor volumes to avoid comparison
of tumor with nontumor tissue. Moreover, the tumors could be
easily delineated on both MR and CT images. Assessment of
potential delineation differences between MR and CT is out-
side the scope of the present study, because we wanted to be
sure that the same tumor tissue regions were assessed for the
pharmacokinetic analysis on MR and CT images.
In conclusion, our study demonstrates for the first
time that both pCT and DCE-MRI are suitable and com-
parable techniques for evaluating tumor perfusion
parameters in rectal cancer. This was shown in terms
of comparisons between tumor average and voxel-by-
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